A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Journalists covering COVID-19 faced an extraordinarily challenging task of keeping the public informed in a hyper-politicized climate filled with misinformation and reliance on unsubstantiated ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

In a new study, researchers investigated the impact of trial study design and other parameters on the estimates of COVID-19 vaccine efficacy.

The Food and Drug Administration released an analysis of Johnson & Johnson's COVID-19 vaccine Wednesday morning that appears to support its authorization for emergency use.

AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier.

Ahead of a U.S Food and Drug Administration advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19. The new ...

CureVac (5CV.DE) said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago.